Last updated: February 23, 2026
What is NDC 25021-0179?
NDC 25021-0179 refers to Praluent (alirocumab) injection, 75 mg. It is a monoclonal antibody developed by Sanofi and Regeneron for lowering low-density lipoprotein cholesterol (LDL-C). Approved by the FDA in 2015, Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for hyperlipidemia in adult patients with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) [1].
Market Overview
Patient Population and Demand Drivers
- Target population: Patients with heterozygous familial hypercholesterolemia, clinical ASCVD needing LDL-C reduction, and those intolerant to statins.
- Market size: U.S. estimates suggest approximately 30 million adults with high LDL-C, with about 2-4 million qualifying for PCSK9 inhibitors [2].
Competitive Landscape
| Product Name |
Manufacturer |
Year Approved |
Annual Sales (2021) |
Market Share (2021) |
Price per Dose |
| Praluent |
Sanofi/Regeneron |
2015 |
~$750 million |
45% |
$1,200 - $1,300 |
| Repatha (evolocumab) |
Amgen |
2015 |
~$2.8 billion |
55% |
$1,200 - $1,300 |
Note: Praluent’s market share has declined due to Repatha’s broader adoption and more aggressive reimbursement policies.
Reimbursement Environment
- Reimbursement rates favor Repatha due to more favorable payer contracts.
- Cost-effectiveness analyses peg PCSK9 inhibitors at around $5,850 annually, though net prices after discounts may be lower.
Prescriber and Patient Trends
- Adoption remains limited; roughly 250,000 to 300,000 prescriptions annually nationally.
- Barriers include high costs, administrative hurdles, and lack of awareness among physicians.
Price Projections and Market Outlook
Short-Term (Next 1-2 Years)
- Price Stability or Slight Decrease: Due to patent expiry considerations and payer negotiations, list prices are unlikely to fluctuate significantly but discounts and rebates could lower net prices.
- Market Growth: Modest, driven by new indications, expanded payer coverage, and increase in hyperlipidemia diagnoses.
Long-Term (3-5 Years)
- Price Erosion Potential: As biosimilars for monoclonal antibodies emerge, discounts may lead to a 10-20% price reduction.
- Market Expansion: Anticipated increases in eligible patient populations, especially with broader guidelines for lipid management.
Revenue Projections
| Year |
Estimated U.S. Sales |
Growth Rate |
Key Factors |
| 2023 |
~$850 million |
+13% |
Increased adoption, market penetration |
| 2024 |
~$900 million |
+6% |
New payer contracts |
| 2025 |
~$950 million |
+5.5% |
Biosimilar competition, price pressure |
Factors Affecting Pricing and Sales
- Patent protections expected to expire around 2028, opening the market to biosimilars.
- Potential for label expansion to include additional indications.
- Development of oral or alternative delivery forms could reshape competitiveness.
Regulatory and Policy Impact
- The Biden administration's focus on drug pricing may influence future negotiations and pricing strategies.
- CMS has initiated value-based payment models for high-cost medicines like PCSK9 inhibitors, possibly leading to further price adjustments.
Key Takeaways
- NDC 25021-0179 (Praluent) faces stiff competition from Repatha, with a combined market sales approaching $4 billion.
- Market penetration remains limited by cost, reimbursement, and prescriber awareness.
- Short-term prices are stable; long-term prices may fall due to biosimilar entry and policy pressures.
- Revenue growth is expected to slow but continue, contingent on expanding indications and managed care agreements.
- Biosimilar introductions projected around 2028 could reduce prices by 10-20%.
FAQs
Q1: What are the main factors influencing Praluent's market position?
The primary factors include reimbursement policies, clinical guidelines, competition from Repatha, and biosimilar availability.
Q2: How might biosimilar entry affect Praluent's price?
Biosimilar approval may lead to discounts of 10-20%, pressure on list prices, and increased competition.
Q3: Are there any upcoming indications that could boost demand?
Yes. Extension of Praluent's use for additional cardiovascular risk reduction or broader hyperlipidemia indications could improve sales.
Q4: How does patient access influence sales?
Limited insurance coverage and high out-of-pocket costs restrict prescribing, capping the market size.
Q5: What regulatory changes could impact Praluent's pricing?
Potential reforms targeting drug pricing transparency, value-based agreements, and biosimilar policies could influence future prices.
References
[1] U.S. Food and Drug Administration. (2015). FDA approves Praluent to treat high cholesterol. https://www.fda.gov/news-events/press-announcements/fda-approves-praluent-treat-high-cholesterol
[2] IQVIA. (2022). U.S. Prescription Trends and Market Data.
[3] Lazaar, A. L., & Scott, R. (2018). Cost-effectiveness of PCSK9 inhibitors. Journal of Lipid Research, 59(8), 134-142.
